Remove Cosmetics Remove FDA Approval Remove Research
article thumbnail

Daxxify, a New Anti-Wrinkle Drug and Botox Competitor is FDA-Approved

XTalks

Daxxify was FDA-approved for similar cosmetic purposes as Botox and other neuromodulators like Dysport and Xeomin. Many people choose to undergo non-invasive cosmetic procedures to prevent or reduce the appearance of signs of aging. By reducing the movement of these muscles, wrinkles become less pronounced over time.

Botox 98
article thumbnail

CBD Research: A Dive into the Regulations of Cannabis Research

Advarra

As such, we are seeing an uptick in research examining the therapeutic effects of cannabis and its constituents. with 37 states approving medicinal use and 18 approving recreationally. While there isn’t a significant amount of research on cannabidiol (CBD), it’s easily accessible in the U.S. Funding Research on Cannabis.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign

The Pharma Data

June 8, 2021 /PRNewswire/ — Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), is changing the way BOTOX ® Cosmetic, the #1 selling neurotoxin treatment 1 , is connecting with consumers. “BOTOX ® Cosmetic is honoring and celebrating the dynamic people who use our products. IRVINE, Calif.

Botox 52
article thumbnail

FDA Approves First COVID-19 Treatment for Young Children

The Pharma Data

director of the FDA’s Center for Drug Evaluation and Research. Today’s approval of the first COVID-19 therapeutic for this population demonstrates the agency’s commitment to that need.”. Learn more about FDA-approved and authorized COVID-19 vaccines. Source link: [link].

article thumbnail

FDA Approves New Imaging Drug to Help Identify Ovarian Cancer Lesions

The Pharma Data

“The FDA’s approval of Cytalux can help enhance the ability of surgeons to identify deadly ovarian tumors that may otherwise go undetected,” said Alex Gorovets, M.D., deputy director of the Office of Specialty Medicine in the FDA’s Center for Drug Evaluation and Research. “By The FDA, an agency within the U.S.

article thumbnail

FDA Approves First Drug to Improve Growth in Children with Most Common Form of Dwarfism

The Pharma Data

“Today’s approval fulfills an unmet medical need for more than 10,000 children in the United States and underscores the FDA’s commitment to help make new therapies available for rare diseases,” said Theresa Kehoe, M.D., director of the Division of General Endocrinology in the FDA’s Center for Drug Evaluation and Research.

article thumbnail

FDA Approves Treatment for Wider Range of Patients with Heart Failure

The Pharma Data

“Today’s approval will provide a treatment option for a wider range of patients with heart failure,” said Norman Stockbridge, M.D., Director of the Division of Cardiology and Nephrology in the FDA’s Center for Drug Evaluation and Research. Source link: [link].